Latest Insider Transactions at Cidara Therapeutics, Inc. (CDTX)
This section provides a real-time view of insider transactions for Cidara Therapeutics, Inc. (CDTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Cidara Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Cidara Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 26
2024
|
Ra Capital Management, L.P. |
BUY
Grant, award, or other acquisition
|
Indirect |
389,716
+26.29%
|
$5,456,024
$14.91 P/Share
|
|
Sep 11
2024
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
909
-4.86%
|
$9,999
$11.64 P/Share
|
|
Sep 11
2024
|
Taylor Sandison Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
924
-3.85%
|
$10,164
$11.64 P/Share
|
|
Jul 19
2024
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
703,080
+50.0%
|
-
|
|
Jun 07
2024
|
Jeffrey Stein President & CEO |
BUY
Open market or private purchase
|
Indirect |
8,000
+24.55%
|
$104,000
$13.21 P/Share
|
|
Mar 15
2024
|
Taylor Sandison Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
128,750
+21.3%
|
-
|
|
Mar 15
2024
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
111,250
+23.12%
|
-
|
|
Mar 15
2024
|
Preetam Shah Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
108,750
+24.45%
|
-
|
|
Mar 15
2024
|
Shane Ward COO & CLO |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+27.35%
|
-
|
|
Mar 11
2024
|
Preetam Shah Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
18,931
-7.69%
|
$0
$0.67 P/Share
|
|
Mar 11
2024
|
Shane Ward COO & CLO |
SELL
Open market or private sale
|
Direct |
20,473
-9.34%
|
$0
$0.67 P/Share
|
|
Mar 11
2024
|
Taylor Sandison Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,662
-5.62%
|
$0
$0.67 P/Share
|
|
Mar 11
2024
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
21,029
-7.52%
|
$0
$0.67 P/Share
|
|
Mar 11
2024
|
Jeffrey Stein President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
56,692
-4.68%
|
$0
$0.69 P/Share
|
|
Sep 11
2023
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
18,469
-6.28%
|
$0
$0.95 P/Share
|
|
Sep 11
2023
|
Taylor Sandison Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,793
-4.91%
|
$0
$0.95 P/Share
|
|
Aug 14
2023
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
BUY
Open market or private purchase
|
Direct |
10,000
+3.29%
|
$0
$0.97 P/Share
|
|
Aug 08
2023
|
Jeffrey Stein President & CEO |
BUY
Open market or private purchase
|
Indirect |
50,000
+13.1%
|
$0
$0.96 P/Share
|
|
Mar 27
2023
|
Jeffrey Stein President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
271,750
+18.43%
|
-
|
|
Mar 27
2023
|
Shane Ward COO & CLO |
BUY
Grant, award, or other acquisition
|
Direct |
126,667
+37.49%
|
-
|
|
Mar 27
2023
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+24.31%
|
-
|
|
Mar 27
2023
|
Taylor Sandison Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+19.21%
|
-
|
|
Mar 27
2023
|
Preetam Shah Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+27.43%
|
-
|
|
Mar 27
2023
|
Jeffrey Stein President & CEO |
BUY
Open market or private purchase
|
Indirect |
50,000
+15.08%
|
$50,000
$1.04 P/Share
|
|
Mar 13
2023
|
Taylor Sandison Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,203
-2.44%
|
$7,203
$1.53 P/Share
|
|
Mar 13
2023
|
Preetam Shah Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,648
-4.29%
|
$6,648
$1.53 P/Share
|
|
Mar 13
2023
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
7,562
-3.82%
|
$7,562
$1.53 P/Share
|
|
Mar 13
2023
|
Shane Ward COO & CLO |
SELL
Open market or private sale
|
Direct |
4,329
-4.87%
|
$4,329
$1.53 P/Share
|
|
Jan 12
2023
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Indirect |
11,814
-88.84%
|
$11,814
$1.2 P/Share
|
|
Sep 19
2022
|
Preetam Shah Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,642
-9.4%
|
$0
$0.77 P/Share
|
|
Sep 15
2022
|
Preetam Shah Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+23.1%
|
-
|
|
Sep 12
2022
|
Taylor Sandison Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,478
-5.96%
|
$0
$0.68 P/Share
|
|
Sep 12
2022
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
18,159
-8.57%
|
$0
$0.68 P/Share
|
|
Sep 12
2022
|
Paul Daruwala Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
16,199
-6.83%
|
$0
$0.68 P/Share
|
|
Mar 31
2022
|
Paul Daruwala Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+17.4%
|
-
|
|
Mar 31
2022
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+20.16%
|
-
|
|
Mar 31
2022
|
Jeffrey Stein President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
140,985
-13.26%
|
$0
$0.83 P/Share
|
|
Mar 31
2022
|
Jeffrey Stein President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
573,742
+23.94%
|
-
|
|
Mar 31
2022
|
Shane Ward COO & CLO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,122
-22.23%
|
$0
$0.83 P/Share
|
|
Mar 31
2022
|
Shane Ward COO & CLO |
BUY
Grant, award, or other acquisition
|
Direct |
104,027
+44.94%
|
-
|
|
Mar 31
2022
|
Taylor Sandison Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+14.04%
|
-
|
|
Mar 31
2022
|
Preetam Shah Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
24,820
-18.08%
|
$0
$0.83 P/Share
|
|
Mar 31
2022
|
Preetam Shah Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
117,251
+37.15%
|
-
|
|
Mar 31
2022
|
Brady Johnson Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+14.42%
|
-
|
|
Mar 21
2022
|
Brady Johnson Vice President, Finance |
SELL
Open market or private sale
|
Direct |
654
-1.31%
|
$0
$0.81 P/Share
|
|
Mar 11
2022
|
Brady Johnson Vice President, Finance |
SELL
Open market or private sale
|
Direct |
945
-1.85%
|
$0
$0.71 P/Share
|
|
Jan 05
2022
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,252
-0.8%
|
$1,252
$1.25 P/Share
|
|
Jan 05
2022
|
Brady Johnson Vice President, Finance |
SELL
Open market or private sale
|
Direct |
416
-0.81%
|
$416
$1.25 P/Share
|
|
Jan 05
2022
|
Paul Daruwala Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
5,133
-2.67%
|
$5,133
$1.25 P/Share
|
|
Dec 29
2021
|
Leslie Tari CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,101
+1.32%
|
-
|